ANEBULO PHARMACEUTICALS INC (ANEB)
US0345691036 - Common Stock
Overall ANEB gets a fundamental rating of 2 out of 10. We evaluated ANEB against 195 industry peers in the Pharmaceuticals industry. While ANEB seems to be doing ok healthwise, there are quite some concerns on its profitability. ANEB has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
ANEB had negative earnings in the past year.
In the past year ANEB has reported a negative cash flow from operations.
In the past 5 years ANEB always reported negative net income.
In the past 5 years ANEB always reported negative operating cash flow.
1.2 Ratios
ANEB has a worse Return On Assets (-320.98%) than 93.55% of its industry peers.
ANEB has a Return On Equity of -417.21%. This is amonst the worse of the industry: ANEB underperforms 80.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -320.98% | ||
| ROE | -417.21% | ||
| ROIC | N/A |
ROA(3y)-115.24%
ROA(5y)-105.79%
ROE(3y)-123.7%
ROE(5y)-111.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ANEB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, ANEB has more shares outstanding
There is no outstanding debt for ANEB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -5.00, we must say that ANEB is in the distress zone and has some risk of bankruptcy.
ANEB has a Altman-Z score of -5.00. This is in the lower half of the industry: ANEB underperforms 66.13% of its industry peers.
ANEB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ANEB has a Current Ratio of 3.45. This indicates that ANEB is financially healthy and has no problem in meeting its short term obligations.
ANEB's Current ratio of 3.45 is in line compared to the rest of the industry. ANEB outperforms 52.15% of its industry peers.
ANEB has a Quick Ratio of 3.45. This indicates that ANEB is financially healthy and has no problem in meeting its short term obligations.
ANEB has a Quick ratio of 3.45. This is comparable to the rest of the industry: ANEB outperforms 55.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.45 | ||
| Quick Ratio | 3.45 |
3. Growth
3.1 Past
ANEB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.78%, which is quite impressive.
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 48.26% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-5.19%
EPS Next 2Y-43.94%
EPS Next 3Y-36.05%
EPS Next 5Y48.26%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ANEB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANEB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ANEB's earnings are expected to decrease with -36.05% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-43.94%
EPS Next 3Y-36.05%
5. Dividend
5.1 Amount
ANEB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ANEBULO PHARMACEUTICALS INC
NASDAQ:ANEB (1/14/2025, 8:23:27 PM)
1.5955
+0.09 (+5.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners28.18%
Inst Owner Change0%
Ins Owners64.22%
Ins Owner Change0%
Market Cap41.37M
Analysts84.44
Price Target6.12 (283.58%)
Short Float %0.66%
Short Ratio1.88
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.79%
Min EPS beat(2)-56.86%
Max EPS beat(2)62.44%
EPS beat(4)2
Avg EPS beat(4)11.97%
Min EPS beat(4)-56.86%
Max EPS beat(4)62.44%
EPS beat(8)5
Avg EPS beat(8)9.11%
EPS beat(12)6
Avg EPS beat(12)0.07%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-50%
EPS NY rev (3m)40%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 21.79 | ||
| P/tB | 21.79 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.66
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -320.98% | ||
| ROE | -417.21% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-115.24%
ROA(5y)-105.79%
ROE(3y)-123.7%
ROE(5y)-111.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.45 | ||
| Quick Ratio | 3.45 | ||
| Altman-Z | -5 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y-5.19%
EPS Next 2Y-43.94%
EPS Next 3Y-36.05%
EPS Next 5Y48.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.44%
OCF growth 3YN/A
OCF growth 5YN/A